Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of trastuzumab emtansine in patients from prior Genentech/Roche T-DM1 trials
jRCT2080223113Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab emtansine in breast cancer and Non-hematologic malignancy (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancerNon-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223113.